Total Payments
$1,092
2022 Payments
$177.16
Companies
18
Transactions
43
Medicare Patients
1,336
Medicare Billing
$419,167
Payment Breakdown by Category
Food & Beverage$1,002 (91.8%)
Education$89.77 (8.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,002 | 36 | 91.8% |
| Education | $89.77 | 7 | 8.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $437.45 | 6 | $0 (2022) |
| PFIZER INC. | $220.75 | 11 | $0 (2021) |
| Janssen Biotech, Inc. | $138.50 | 9 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $46.92 | 2 | $0 (2018) |
| TESARO, Inc. | $30.00 | 1 | $0 (2017) |
| Astellas Pharma US Inc | $29.77 | 2 | $0 (2017) |
| Incyte Corporation | $24.55 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $19.88 | 1 | $0 (2017) |
| AbbVie, Inc. | $18.75 | 1 | $0 (2018) |
| Lilly USA, LLC | $18.08 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $177.16 | 4 | AstraZeneca Pharmaceuticals LP ($151.17) |
| 2021 | $324.78 | 7 | AstraZeneca Pharmaceuticals LP ($270.52) |
| 2020 | $67.61 | 5 | PFIZER INC. ($38.29) |
| 2019 | $40.42 | 3 | Janssen Biotech, Inc. ($40.42) |
| 2018 | $318.34 | 15 | PFIZER INC. ($156.72) |
| 2017 | $163.52 | 9 | TESARO, Inc. ($30.00) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/27/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $126.21 | General |
| Category: Oncology | ||||||
| 04/18/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: Oncology | ||||||
| 03/21/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Oncology | ||||||
| 02/24/2022 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $11.87 | General |
| Category: Oncology | ||||||
| 12/17/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.16 | General |
| 11/11/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $121.36 | General |
| 08/05/2021 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA, INVEGA | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: Neuroscience | ||||||
| 07/14/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 03/25/2021 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 03/24/2021 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2020 | PFIZER INC. | INLYTA (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Oncology | ||||||
| 02/26/2020 | PFIZER INC. | XALKORI (Drug) | Education | In-kind items and services | $13.90 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2020 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $11.05 | General |
| Category: ONCOLOGY | ||||||
| 01/14/2020 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Oncology | ||||||
| 11/18/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Oncology | ||||||
| 10/24/2019 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Oncology | ||||||
| 09/20/2019 | Janssen Biotech, Inc. | CERTUS 140 MICROWAVE ABLATION SYSTEM (Device) | Food and Beverage | In-kind items and services | $11.04 | General |
| Category: Interventional Solutions | ||||||
| 12/17/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $4.35 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $121.41 | General |
| Category: ONCOLOGY | ||||||
| 09/21/2018 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $24.55 | General |
| Category: Hematology/Oncology | ||||||
| 09/11/2018 | AbbVie, Inc. | Venclexta (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Virology | ||||||
| 06/27/2018 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 118 | 214 | $47,570 | $15,174 |
| 2022 | 5 | 195 | 4,212 | $646,861 | $87,845 |
| 2021 | 12 | 441 | 4,433 | $988,079 | $157,757 |
| 2020 | 17 | 582 | 6,614 | $1.0M | $158,391 |
Total Patients
1,336
Total Services
15,473
Medicare Billing
$419,167
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 62 | $18,704 | $6,249 | 33.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $12,112 | $3,530 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 15 | 30 | $8,964 | $3,216 | 35.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 40 | 95 | $7,790 | $2,179 | 28.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 11 | 3,840 | $507,833 | $65,597 | 12.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 116 | 119 | $68,299 | $10,959 | 16.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 43 | 72 | $54,231 | $10,052 | 18.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 14 | 82 | $11,398 | $1,056 | 9.3% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2022 | 11 | 99 | $5,100 | $179.99 | 3.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 13 | 3,420 | $434,063 | $56,695 | 13.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 83 | 201 | $155,373 | $32,949 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 180 | 251 | $144,827 | $25,456 | 17.6% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 18 | 167 | $152,350 | $25,412 | 16.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 25 | 43 | $23,272 | $4,030 | 17.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $22,964 | $3,996 | 17.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 17 | 17 | $18,445 | $3,396 | 18.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 13 | 18 | $3,294 | $1,888 | 57.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 29 | $10,867 | $1,825 | 16.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 19 | 79 | $9,164 | $1,049 | 11.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 18 | 23 | $3,680 | $702.65 | 19.1% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2021 | 19 | 163 | $9,780 | $358.41 | 3.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 13 | 4,080 | $433,739 | $63,479 | 14.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 206 | 338 | $192,992 | $29,423 | 15.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 23 | 179 | $149,580 | $25,591 | 17.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 40 | 55 | $42,092 | $7,328 | 17.4% |
About Dr. Jennifer Brown, M.D
Dr. Jennifer Brown, M.D is a Hematology & Oncology healthcare provider based in San Mateo, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1740347350.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jennifer Brown, M.D has received a total of $1,092 in payments from pharmaceutical and medical device companies, with $177.16 received in 2022. These payments were reported across 43 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($1,002).
As a Medicare-enrolled provider, Brown has provided services to 1,336 Medicare beneficiaries, totaling 15,473 services with total Medicare billing of $419,167. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location San Mateo, CA
- Active Since 01/02/2007
- Last Updated 06/08/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1740347350
Products in Payments
- IBRANCE (Drug) $169.12
- LYNPARZA (Drug) $126.21
- IMBRUVICA (Drug) $112.95
- KISQALI (Drug) $46.92
- VARUBI (Drug) $30.00
- INLYTA (Drug) $26.68
- ENHERTU (Biological) $24.96
- JAKAFI (Drug) $24.55
- Venclexta (Drug) $18.75
- Tarceva (Drug) $18.32
- ALIMTA (Drug) $18.08
- IMFINZI (Drug) $15.76
- Nplate (Biological) $15.58
- INVEGA SUSTENNA (Drug) $15.07
- DARZALEX (Biological) $14.51
- BENDEKA (Drug) $14.02
- BELEODAQ (Drug) $13.93
- XALKORI (Drug) $13.90
- Xermelo (Drug) $13.27
- ADCETRIS (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Mateo
Julian Mclain, Md, MD
Hematology & Oncology — Payments: $6,311
Hematology & Oncology $6,311
Dr. Karen Chee, M.d, M.D
Hematology & Oncology — Payments: $2,132
Hematology & Oncology $2,132
Katrina Fischer
Hematology & Oncology — Payments: $1,958
Hematology & Oncology $1,958
Bradley Ekstrand, M.d., Ph.d, M.D., PH.D
Hematology & Oncology — Payments: $1,619
Hematology & Oncology $1,619
Kent Adler, M.d, M.D
Hematology & Oncology — Payments: $1,491
Hematology & Oncology $1,491
Dr. Jelena Kao, Md, MD
Hematology & Oncology — Payments: $638.03
Hematology & Oncology $638.03